The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Open accessAbstract
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V 1a , V 1b and V 2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V 1b receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V 1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V 2 /V 1a antagonist, conivaptan and the V 2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V 1a , V 1b and V 2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these compounds bind selectively to their respective receptors in rodents, they have now been shown to exhibit relatively high affinities for both OXTR and AVPR1a in primates (27,28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“Simply comparing the binding characteristics of the most common ligands for the human and rat OT and AVP receptors reveals considerable variation in pharmacological properties across species (28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“For example, studies employing recombinant expression systems to examine selectivity of human, rat, and mouse OT and AVP receptors have shown that only the human OTR is selective for OT using a standard criterion [34; 35] (Table 1).”
From Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery (2018) · cites this paper as [35]
In the citing paper
“The limited information on the distributions of OTR and V1aR in primate neural tissue is due in part to the lower selectivity for radioligands targeting OTR (125I-OVTA) and V1aR (125I-LVA) autoradiography, relative to high selectivity of radioligands for these receptors in rodents, as well as the promiscuous binding profile of both radioligands for OTR and V1aR (Freeman et al., 2014a, 2014b; Man”
From Neuropeptide diversity and the regulation of social behavior in New World primates (2016) · cites this paper as Manning et al., 2012
In the citing paper
“There was also no difference in AVP levels, suggesting no peripheral cross-reactivity, which is more likely to occur with higher levels of oxytocin exposure.71”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Damm, T. B., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,552
Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,825
Inositol Trisphosphate, a Novel Second Messenger in Cellular Signal Transduction
Berridge, M. J., & Irvine, R. F. (1984) · Nature · doi:10.1038/312315a0 · Cited by 6,086
A highly sensitive adenylate cyclase assay
Salomon, Y., Londos, C., & Rodbell, M. (1974) · Analytical Biochemistry · doi:10.1016/0003-2697(74)90222-x · Cited by 4,135
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Stewart, J. M. (1976) · Journal of Macromolecular Science Part A - Chemistry · doi:10.1080/00222337608068099 · Cited by 1,770
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martínez, J., & Khrestchatisky, M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,523
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Research works printed but not linked: 13
- Manning M, 1981, The Pituitary, 265
- Manning M, 1985, Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin, 131
- Manning M, 1991, Vasopressin, 297
- Manning M, 2005, Peptides 2004, 101
- Lebl M, 1988, Handbook of Neurohypophyseal Hormone Analogs, 17
- Jard S, 1998, Adv Exp Med Biol, 1
- 10.1210/en.137.9.3906 · DOI
- Wisniewski K, 2010, Peptides 2010, 306
- Manning M, 2010, Peptides 2010, 366
- Guillon G, 2007, Peptides 2006, 742
- 10.1021/jm010526 · DOI
- Mimoun MB, 2001, Peptides 2000, 589
- Reichert J, 2010, Development Trends for Peptide Therapeutics
Cited by
Sorted by citations
Items 201–300 of 429
Oxytocin and vasopressin increase male-directed threats and vocalizations in female macaques
Jiang, Y., & Platt, M. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-36332-0 · Cited by 20
Peptide Hormones in Medicine: A 100-Year History
Мартинович, В. П., & Baradzina, K. U. (2022) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162022020157 · Cited by 19
Over-expression of V1A receptors in PVN modulates autonomic cardiovascular control
Lozić, M., Tasić, T., Martin, A., Greenwood, M. P., Šarenac, O., Hindmarch, C. C. T., Paton, J. F. R., Murphy, D., & Japundžić‐Žigon, N. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.024 · Cited by 19
Dong, N., Du, P., Hao, X., He, Z., Hou, W., Wang, L., Yuan, W., Yang, J., Jia, R., & Tai, F. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.07.006 · Cited by 20
Dekan, Z., Kremsmayr, T., Keov, P., Godin, M., Teakle, N., Duerrauer, L., Xiang, H., Gharib, D., Bergmayr, C., Hellinger, R., et al. (2021) · Chemical Science · doi:10.1039/d0sc05501h · Cited by 19
Preventive Effects of Oxytocin and Oxytocin Receptor in Breast Cancer Pathogenesis
Ariana, M., Pornour, M., Mehr, S. S., Vaseghi, H., Ganji, S. M., Alivand, M. R., Salari, M., & Akbari, M. E. (2018) · Personalized Medicine · doi:10.2217/pme-2018-0009 · Cited by 19
Taylor, J. H., McCann, K. E., Ross, A. P., & Albers, H. E. (2020) · Journal of Neuroendocrinology · doi:10.1111/jne.12882 · Cited by 18
Orally administered oxytocin alters brain activation and behaviors of pre-weaning mice
Tabbaa, M., & Hammock, E. A. D. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.104613 · Cited by 18
Baran, N. M., Tomaszycki, M. L., & Adkins–Regan, E. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00058 · Cited by 20
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers
Kalaba, P., de la Rosa, C. S., Möller, A., Alewood, P. F., & Muttenthaler, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01089 · Cited by 19
Collins, J. S., Kempe, K., Wilson, P., Blindauer, C. A., McIntosh, M. P., Davis, T. P., Whittaker, M. R., & Haddleton, D. M. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b00919 · Cited by 17
Walker, W. H., Meléndez-Fernández, O. H., Pascoe, J. L., Zhang, N., & DeVries, A. (2020) · Brain, behavior, and immunity · doi:10.1016/j.bbi.2020.07.032 · Cited by 17
Gniazdowska, E., Koźmiński, P., Bańkowski, K., & Ochman, P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500272r · Cited by 17
Navigating Central Oxytocin Transport: Known Realms and Uncharted Territories
Parmaksiz, D., & Kim, Y. (2024) · The Neuroscientist · doi:10.1177/10738584241268754 · Cited by 21
Chapter 4. Psychoneuroendocrinology
Sforzini, L., Weston, F. I., & Pariante, C. M. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as04 · Cited by 16
Korpal, A. K., Han, S. Y., Schwenke, D. O., & Brown, C. H. (2017) · Journal of Neuroendocrinology · doi:10.1111/jne.12564 · Cited by 16
Mohan, S., McCloskey, A. G., McKillop, A. M., Flatt, P. R., Irwin, N., & Moffett, R. C. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129811 · Cited by 16
Brackley, A. D., & Toney, G. M. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000535 · Cited by 14
Lind, C. M., Birky, N. K., Porth, A. M., & Farrell, T. M. (2017) · Biology Open · doi:10.1242/bio.022616 · Cited by 15
Pastrián, M. B., Guzmán, F., Garona, J., Pífano, M., Ripoll, G. V., Cascone, O., Ciccia, G., Alberício, F., Gomez, D. E., Alonso, D. F., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2140 · Cited by 15
Leu8 and Pro8 oxytocin agonism differs across human, macaque, and marmoset vasopressin 1a receptors
Mustoe, A. C., Schulte, N. A., Taylor, J. H., French, J. A., & Toews, M. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-52024-9 · Cited by 15
Inutsuka, A., Ino, D., & Onaka, T. (2020) · Peptides · doi:10.1016/j.peptides.2020.170456 · Cited by 16
Chronic central oxytocin infusion impairs sociability in mandarin voles
Du, P., He, Z., Cai, Z., Hao, X., Dong, N., Yuan, W., Hou, W., Yang, J., Jia, R., & Tai, F. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.09.006 · Cited by 14
Cafarchio, E. M., Auresco, L. C., da Silva, L. A., Rodart, I. F., Vale, B. D. M., de Souza, J. S., Antonio, B. B., Venâncio, D. P., Giannocco, G., Aronsson, P., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.024 · Cited by 15
Lukas, M., Suyama, H., & Egger, V. (2019) · eNeuro · doi:10.1523/eneuro.0431-18.2019 · Cited by 15
Vasopressin and oxytocin excite BNST neurons via oxytocin receptors, which reduce anxious arousal
Francesconi, W., Olivera-Pasilio, V., Berton, F., Olson, S. L., Chudoba, R., Monroy, L. M., Krabichler, Q., Grinevich, V., & Dabrowska, J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115768 · Cited by 14
Conformation and dynamics of 8-Arg-vasopressin in solution
Haensele, E., Banting, L., Whitley, D. C., & Clark, T. (2014) · Journal of Molecular Modeling · doi:10.1007/s00894-014-2485-0 · Cited by 14
Oxytocin/vasopressin-like neuropeptide signaling in insects
Muratspahić, E., Monjon, E., Duerrauer, L., Rogers, S. M., Cullen, D. A., Broeck, J. V., & Gruber, C. W. (2020) · Vitamins and hormones · doi:10.1016/bs.vh.2019.08.011 · Cited by 15
Oliveira, V. E. D. M., A, T. R. D. J., & Neumann, I. D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.906617 · Cited by 13
Behavioral Roles of Oxytocin and Vasopressin
Benjamin, C. (2012) · InTech eBooks · doi:10.5772/50422 · Cited by 14
From ethnopharmacology to drug design
Koehbach, J., & Gruber, C. W. (2013) · Communicative & Integrative Biology · doi:10.4161/cib.27583 · Cited by 14
Synthetic approaches of naturally and rationally designed peptides and peptidomimetics
Lobo‐Ruiz, A., & Tulla‐Puche, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100736-5.00002-8 · Cited by 14
Taylor, J. H., Schulte, N. A., French, J. A., & Toews, M. L. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.250852 · Cited by 14
Pierce, M. L., French, J. A., & Murray, T. F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110060 · Cited by 14
Macrocyclic-based strategy in drug design: From lab to the clinic
Jin, X., Ding, N., Guo, H., & Hu, Q. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116733 · Cited by 13
Oxytocin Analogues for the Oral Treatment of Abdominal Pain
Kremsmayr, T., Schober, G., Kaltenböck, M., Hoare, B. L., Brierley, S. M., & Muttenthaler, M. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202415333 · Cited by 13
Leng, G., & Russell, J. A. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12331 · Cited by 13
Potent and selective oxytocin receptor agonists without disulfide bridges
Adachi, Y., Sakimura, K., Shimizu, Y., Nakayama, M., Terao, Y., Yano, T., & Asami, T. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.030 · Cited by 13
Buron, J., Linossier, A., Gestreau, C., Schaller, F., Tyzio, R., Félix, M., Matarazzo, V. A., Thoby‐Brisson, M., Muscatelli, F., & Menuet, C. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02074-2 · Cited by 13
Oxytocin modulates mate-guarding behavior in marmoset monkeys
Cavanaugh, J., Mustoe, A. C., Womack, S. L., & French, J. A. (2018) · Hormones and Behavior · doi:10.1016/j.yhbeh.2018.10.009 · Cited by 13
Lee, J., Reppucci, C. J., Bowden, S. M., Huez, E. D. M., Bredewold, R., & Veenema, A. H. (2021) · Hormones and Behavior · doi:10.1016/j.yhbeh.2024.105563 · Cited by 11
Araishi, K., Watanabe, K., Yamazaki, T., Nakamachi, T., & Matsuda, K. (2019) · Peptides · doi:10.1016/j.peptides.2019.170118 · Cited by 12
Admane, N., Srivastava, A., Jamal, S., Kundu, B., & Grover, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00299 · Cited by 12
Uba, A. İ., Radicella, C., Readmond, C., Scorese, N., Liao, S., Liu, H., & Wu, C. F. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117643 · Cited by 13
A Three‐Site Mechanism for Agonist/Antagonist Selective Binding to Vasopressin Receptors
Saleh, N., Saladino, G., Gervasio, F. L., Haensele, E., Banting, L., Whitley, D. C., Santos, J. S. O., Bureau, R., & Clark, T. (2016) · Angewandte Chemie · doi:10.1002/ange.201602729 · Cited by 12
Discovery of Potent, Selective, and Short-Acting Peptidic V 2 Receptor Agonists
Wiśniewski, K., Qi, S., Kraus, J., Ly, B., Srinivasan, K., Tariga, H., Croston, G. E., La, E., Wiśniewska, H., Ortíz, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00132 · Cited by 11
I8-arachnotocin–an arthropod-derived G protein-biased ligand of the human vasopressin V2 receptor
Duerrauer, L., Muratspahić, E., Gattringer, J., Keov, P., Mendel, H. C., Pfleger, K. D. G., Muttenthaler, M., & Gruber, C. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-55675-w · Cited by 16
Oxytocin modulates human chemosensory decoding of sex in a dose-dependent manner
Chen, K.-P., Ye, Y.-T., Troje, N., & Zhou, W. (2021) · eLife · doi:10.7554/elife.59376 · Cited by 12
Robust Reductions of Body Weight and Food Intake by an Oxytocin Analog in Rats
Elfers, C., Blevins, J. E., Lawson, E. A., Pittner, R. A., Silva, D., Kiselyov, A. S., & Roth, C. L. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.726411 · Cited by 11
Conformational selection of vasopressin upon V 1a receptor binding
Che, K., Muttenthaler, M., & Kurzbach, D. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.10.024 · Cited by 11
Hu, S., Wang, Y., Han, X., Dai, M., Zhang, Y., Ma, Y., Weng, S.-J., & Xiao, L. (2022) · BMC Biology · doi:10.1186/s12915-022-01405-0 · Cited by 11
Dumais, K. M., & Veenema, A. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802114-9.00011-1 · Cited by 11
Molecular Mechanisms Involved in the Control of Neurohypophyseal Hormones Secretion
Iovino, M., Guastamacchia, E., Giagulli, V. A., Licchelli, B., Iovino, E., & Triggiani, V. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140905150730 · Cited by 11
Triki, Z., Bshary, R., Grutter, A. S., & Ros, A. F. H. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.011 · Cited by 10
Photoswitchable Probes of Oxytocin and Vasopressin
Wirth, U., Raabe, K., Kalaba, P., Keimpema, E., Muttenthaler, M., & König, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01415 · Cited by 10
Hus-Citharel, A., Bouby, N., Corbani, M., Mion, J., Mendre, C., Darusi, J., Tömböly, C., Trueba, M., Gal, C. S., Llorens‐Cortés, C., et al. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00081.2021 · Cited by 11
Self-citationTaylor, J. H., & Grieb, Z. A. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.100996 · Cited by 10
Vasopressin as a Stress Hormone
Antoni, F. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802175-0.00009-7 · Cited by 13
Kang, S. W., Jayanthi, S., Nagarajan, G., Kumar, T. K. S., & Kuenzel, W. J. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1464957 · Cited by 10
Erfanparast, A., Tamaddonfard, E., & Seyedin, S. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2018.26302.6449 · Cited by 10
Truse, R., Grewe, S., Herminghaus, A., Schulz, J., Weber, A. P. M., Mettler‐Altmann, T., Bauer, I., Picker, O., & Vollmer, C. (2019) · Critical Care · doi:10.1186/s13054-019-2643-y · Cited by 12
Central but not peripheral oxytocin administration reduces risk-based decision-making in male rats
Tapp, D. N., Singstock, M., Gottliebson, M. S., & McMurray, M. S. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104840 · Cited by 10
Oxytocin and object preferences in the male prairie vole
Madularu, D., Athanassiou, M., Yee, J. R., Kenkel, W. M., Carter, C. S., & Mumby, D. G. (2014) · Peptides · doi:10.1016/j.peptides.2014.08.015 · Cited by 11
Novel oxytocin receptor agonists and antagonists: a patent review (2002 – 2013)
Yang, Y., Li, H., Ward, R. J., Gao, L., Wei, J., & Xu, T. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.845168 · Cited by 10
The Effects of Acute Arginine Vasopressin Administration on Social Cognition in Healthy Males
Kenyon, A. R., Alvares, G. A., Hickie, I. B., & Guastella, A. J. (2013) · Journal of Hormones · doi:10.1155/2013/386306 · Cited by 10
Wsół, A., Wojno, O., Puchalska, L., Wrzesień, R., Szczepanska‐Sadowska, E. K., & Cudnoch‐Jędrzejewska, A. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00050.2019 · Cited by 10
Vasopressin and Oxytocin: Keys to Understanding the Neural Control of Physiology and Behaviour
Vries, G. J. D., Veenema, A. H., & Brown, C. H. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02305.x · Cited by 10
Extracellular sodium regulates fibroblast growth factor 23 (FGF23) formation
Radvanyi, Z., Yoo, E. J., Kandasamy, P., Salas-Bastos, A., Monnerat, S., Refardt, J., Christ-Crain, M., Hayashi, H., Kondo, Y., Jantsch, J., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105480 · Cited by 9
Horie, K., Blumenthal, S. A., Inoue, K., Yada, S., Nishimori, K., & Young, L. J. (2025) · Hormones and Behavior · doi:10.1016/j.yhbeh.2025.105708 · Cited by 8
Inada, K., Hagihara, M., Yaguchi, K., Irie, S., Inoue, Y., Inoue, T., & Miyamichi, K. (2025) · Nature Communications · doi:10.1038/s41467-025-66908-0 · Cited by 12
Ikeda, N., Kawasaki, M., Baba, K., Nishimura, H., Fujitani, T., Suzuki, H., Matsuura, T., Ohnishi, H., Shimizu, M., Sanada, K., et al. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.07.028 · Cited by 10
Cyclotides: a natural combinatorial peptide library or a bioactive sequence player?
Mollica, A., Costante, R., Stefanucci, A., & Novellino, E. (2014) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2014.954108 · Cited by 9
Khan, M., Huang, T., Lin, C., Wu, J., Fan, B.-M., & Bian, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.18403 · Cited by 9
Nonapeptide Receptor Distributions in Promising Avian Models for the Neuroecology of Flocking
Ondrasek, N. R., Freeman, S. M., Bales, K. L., & Calisi, R. M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00713 · Cited by 9
Dolle, A., Nagati, V., Hunashal, Y., Krishnamurthy, K., Pasupulati, A. K., Raghothama, S., & Gowd, K. H. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13525 · Cited by 9
Garona, J., Pífano, M., Ripoll, G. V., & Alonso, D. F. (2020) · Vitamins and hormones · doi:10.1016/bs.vh.2019.08.010 · Cited by 9
Pérez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9060651 · Cited by 10
Higuchi, Y., & Arakawa, H. (2022) · Hormones and Behavior · doi:10.1016/j.yhbeh.2022.105128 · Cited by 9
Das, S., Komnenov, D., Newhouse, L., Rishi, A. K., & Rossi, N. F. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113867 · Cited by 9
Liu, H., & Muttenthaler, M. (2022) · Biomedicines · doi:10.3390/biomedicines10071595 · Cited by 10
Structures of the arginine-vasopressin and oxytocin receptor signaling complexes
Bous, J., Fouillen, A., Orcel, H., Granier, S., Bron, P., & Mouillac, B. (2023) · Vitamins and hormones · doi:10.1016/bs.vh.2022.12.003 · Cited by 9
Self-citationŚlusarz, M. J., Sikorska, E., & Ślusarz, R. (2013) · Journal of Peptide Science · doi:10.1002/psc.2485 · Cited by 9
Neuroendocrinology and Behavior
Sumiyoshi, T. (2012) · InTech eBooks · doi:10.5772/1666 · Cited by 9
Arakawa, H., & Higuchi, Y. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104597 · Cited by 8
Rea, J. J., Liu, C. M., Hayes, A., Ohan, R., Schwartz, G. M., Bashaw, A. G., Klug, M. E., Décarie-Spain, L., Park, Y., Kao, A. E., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102220 · Cited by 9
Yamasue, H. (2023) · Peptides · doi:10.1016/j.peptides.2023.171133 · Cited by 9
Goncharova, N. D., Chigarova, О. А., & Oganyan, T. E. (2018) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-018-4294-4 · Cited by 8
Effects of optogenetic stimulation of vasopressinergic retinal afferents on suprachiasmatic neurones
Hume, C., Allchorne, A. J., Grinevich, V., Leng, G., & Ludwig, M. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12806 · Cited by 8
Desmopressin Stimulates Nitric Oxide Production in Human Lung Microvascular Endothelial Cells
Rotoli, B. M., Visigalli, R., Ferrari, F., Ranieri, M., Tamma, G., Dall’Asta, V., & Barilli, A. (2022) · Biomolecules · doi:10.3390/biom12030389 · Cited by 8
Rethinking the Architecture of Attachment: New Insights into the Role for Oxytocin Signaling
Berendzen, K. M., & Manoli, D. S. (2022) · Affective Science · doi:10.1007/s42761-022-00142-5 · Cited by 9
Marir, R., Virsolvy, A., Wiśniewski, K., Mion, J., Haddou, D., Galibert, E., Meraïhi, Z., Desarménien, M. G., & Guillon, G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12249 · Cited by 9
Self-citationVasotocin analogues with selective natriuretic, kaliuretic and antidiuretic effects in rats
Кутина, А. В., Marina, A. S., Ei, S., & IuV, N. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.06.013 · Cited by 8
Dissociation of natriuresis and diuresis by oxytocin molecular forms in rats
Jankowski, M., Danalache, B. A., Plante, É., Ménaouar, A., Florian, M., Tan, J. J., Grygorczyk, R., Broderick, T. L., & Gutkowska, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219205 · Cited by 8
Wong, S., Brown, A. D., Abrahams, A. B., Nurzak, A. N., Eltaher, H. M., Sykes, D. A., Veprintsev, D. B., Fone, K. C. F., Dixon, J. E., & King, M. V. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101267 · Cited by 7
Fujiwara, T., Kofuji, T., & Akagawa, K. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113447 · Cited by 6
Boumansour, L., Benhafri, N., Guillon, G., Corbani, M., Touati, H., Dekar-Madoui, A., & Ouali‐Hassenaoui, S. (2021) · Animal Cells and Systems · doi:10.1080/19768354.2021.1986130 · Cited by 7
Self-citationBrighton, P. J., Fossler, M. J., Quenby, S. M., & Blanks, A. M. (2020) · Endocrinology · doi:10.1210/endocr/bqz043 · Cited by 7
Non-peptide oxytocin receptor ligands and hamster circadian wheel running rhythms
Gannon, R. L. (2014) · Brain Research · doi:10.1016/j.brainres.2014.08.034 · Cited by 6
Freeman, S. M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1759-5_7 · Cited by 7
Calvillo-Robledo, A., Ramírez-Farías, C., Valdez‐Urias, F., Huerta-Carreón, E. P., & Quintanar‐Stephano, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1138627 · Cited by 6
Metadata
- Authors
- Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G.
- Affiliations
- University of Toledo (US)
- University of Warsaw (PL)
- Lodz University of Technology (PL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Manning, M.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2012-03-26
- Volume
- 24
- Issue
- 4
- Pages
- 609-628
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- PMC
- PMC3490377
- OpenAlex
- W1803779312
- Cited by
- 423
- References
- 244
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 22 · 2023: 25 · 2022: 32 · 2021: 36 · 2020: 31 · 2019: 40 · 2018: 34 · 2017: 35 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 30 · 2012: 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroendocrinology (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Centre National de la Recherche Scientifique
- National Institute of General Medical Sciences (GM25280, R01GM025280)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- oxytocin, vasopressin, vasopressin receptor, oxytocin receptor, V1a receptor, V1b receptor, V2 receptor, peptide agonists, peptide antagonists, conivaptan, tolvaptan, fluorescent ligands, receptor localization, receptor dimerization, oxytocin analogues, receptor selectivity, species differences
- MeSH terms
- Animals, Arginine Vasopressin, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Oxytocin, Structure-Activity Relationship, Receptors, Vasopressin, Receptors, Oxytocin, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
